Cuevas-Gonzlez JC, Vega-Memje
ME, Garca-Vzquez FJ, Rodrguez-Lobato E, Farfn-Morales JE. Apoptosis and apoptotic pathway in actinic prurigo
by immunohistochemistry. Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21
(1):e53-8.
doi:10.4317/medoral.20765
http://dx.doi.org/doi:10.4317/medoral.20765
|
1.
Vera-Izaguirre DS, Zuloaga-Salcedo S, Gonzlez-Snchez PC, Snchez-Lara K,
Chvez-Tapia N, Hojyo-Tomoka MT, et al. Actinic prurigo: a case-control study
of risk factors. Int J Dermatol. 2014;53:1080-5. |
|
|
|
|
|
2.
Vega-Memije ME, Mosqueda-Taylor A, Irigoyen-Camacho
ME, Hojyo-Tomoka MT, Domnguez-Soto L. Actinic prurigo cheilitis: clinicopathologic analysis and therapeutic results in 116
cases. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 2002;94:83-91. |
|
|
|
|
|
3. Hojyo-Tomoka T, Granados J, Vargas-Alarcn G, Yamamoto-Furusho JK, Vega-Memije
E, Corts-Franco R, et al. Further evidence of the role of HLA-DR4
in the genetic susceptibility to actinic prurigo. J Am Acad Dermatol. 1997;36:935-7. |
|
|
|
|
|
4. Grabczynska SA, McGregor JM, Kondeatis E, Vaughan RW, Hawk JL. Actinic prurigo and polymorphic light eruption: common pathogenesis and the importance of
HLA-DR4/DRB1*0407. Br J Dermatol. 1999;140:232-6. |
|
|
|
|
|
5. Wiseman MC, Orr PH, Macdonald SM, Schroeder ML, Toole
JW. Actinic prurigo: clinical
features and HLA associations
in a Canadian Inuit population. J Am Acad Dermatol. 2001;44:952-6. |
|
|
|
|
|
6. Hojyo-Tomoka MT, Vega-Memije
ME, Cortes-Franco R, Domnguez-Soto L. Diagnosis and treatment
of actinic prurigo. Dermatol
Ther. 2003;16:40-4. |
|
|
|
|
|
7. Hojyo-Tomoka T, Vega-Memije E,
Granados J, Flores O, Corts-Franco R, Teixeira F, et al. Actinic
prurigo: an update. Int J Dermatol. 1995;34:380-4. |
|
|
|
|
|
8. Arrese JE, Domnguez L, Hojyo
MT, Vega E, Corts R, Guevara E, et al. Effectors
of inflammation in actinic
prrigo. J Am Acad Dermatol. 2001;44:957-61. |
|
|
|
|
|
9.
Cuevas JC, Garca FJ, Rodrguez E, Farfn JE, Vega ME. Determination
of apoptosis in actinic prurigo by
TUNEL technique. Photodermatol
Photoimmunol Photomed.
2015;31:115-7. |
|
|
|
|
|
10.
Moncada B, Gonzlez-Amaro R, Baranda ML, Loredo C, Urbina R. Immunopathology of polymorphous
light eruption. T lymphocytes
in blood and skin. J Am Acad Dermatol. 1984;10:970-3. |
|
|
|
|
|
11. Evan G, Littlewood T. A matter of life and cell death. Science.
1998;281:1317-22. |
|
|
|
|
|
12. Fraser A, Evan G. A license to kill.
Cell. 1996;85:781-4. |
|
|
|
|
|
13. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and
CPP32-like proteases during
Fas-mediated apoptosis. Nature.
1996;380:723-6. |
|
|
|
|
|
14. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in
Fas/APO-1- and TNF receptor-induced cell death. Cell.
1996;85:803-15. |
|
|
|
|
|
15. Zarnescu O, Brehar FM, Chivu M, Ciurea AV. Immunohistochemical localization
of caspase-3, caspase-9 and Bax in U87 glioblastoma xenografts. J Mol Histol. 2008;39:561-9. |
|
|
|
|
|
16. Lalier L, Cartron PF, Olivier
C, Log C, Bougras G,
Robert JM, et al. Prostaglandins antagonistically control Bax activation during apoptosis. Cell Death Differ.
2011;18:528-37. |
|
|
|
|
|
17. Krohn AJ, Preis E, Prehn JH. Staurosporine-induced
apoptosis of cultured rat
hippocampal neurons involves caspase-1-like proteases
as upstream initiators
and increased production
of superoxide as a main downstream effector. J Neurosci. 1998;18:8186-97. |
|
|
|
|
|
18. Elinos-Bez CM, Maldonado V, Melndez-Zajgla
J. [Caspases: apoptosis inducing
molecules]. Gac Med Mex. 2003;139:493-9. |
|
|
|
|
|
19.
Flores ER, Tsai KY, Crowley
D, Sengupta S, Yang A, McKeon F, et al. p63 and p73
are required for
p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560-4. |
|
|
|
|